Patients who received vandetanib had longer PFS than did those who received placebo ( hazard ratio [ HR ] 063 , 60 % CI 054-074 ; one-sided p = 0008 ) : median PFS was 111 months ( 95 % CI 77-140 ) for patients in the vandetanib group and 59 months ( 40-89 ) for patients in the placebo group .
